Back to News
Market Impact: 0.3
Sionna Advances New CF Combo To Phase 2a After SION-719 Setback, Cuts Workforce 46%; Stock Down
Source: Nasdaq
Healthcare & BiotechProduct Launches
Sionna Therapeutics plans to advance its SION-451 plus SION-2222 dual combination into the AscenSION CF Phase 2a proof-of-concept trial for cystic fibrosis. The clinical progression is a positive development for the company’s pipeline, though efficacy and safety data have not yet been reported.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
SION0.55
More News
- Citizens reiterates Market Perform on Sionna Therapeutics stock
- Wells Fargo sees improvement in a key metric — plus, Lilly gets praise beyond GLP-1s
- Beta Bionics prices $150M public offering at $17.25/share
- Inside South Korea’s university programs offering a direct route to Samsung and SK Hynix
- SpaceX will try to put Starship in orbit for the first time on September 22
- A sharp stock market decline could lie around the corner, Wells Fargo warns